News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Newly Published Study Finds VIVUS, Inc. (VVUS)'s Qsymia Achieves Greater Weight Loss at Lower Doses Than Either of Its Components as Monotherapy


10/31/2013 9:44:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today that a newly-published study demonstrated Qsymia® (phentermine and topiramate extended-release) capsules CIV produced significantly greater weight loss, and at lower doses, compared to phentermine or topiramate administered as monotherapies in obese adults. Among patients taking the once-daily extended-release formulation, Qsymia was generally well tolerated and improved blood pressure. In this study, the effect of Qsymia on heart rate was similar to placebo.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES